ZA201409194B - Biflourodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents
Biflourodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disordersInfo
- Publication number
- ZA201409194B ZA201409194B ZA2014/09194A ZA201409194A ZA201409194B ZA 201409194 B ZA201409194 B ZA 201409194B ZA 2014/09194 A ZA2014/09194 A ZA 2014/09194A ZA 201409194 A ZA201409194 A ZA 201409194A ZA 201409194 B ZA201409194 B ZA 201409194B
- Authority
- ZA
- South Africa
- Prior art keywords
- biflourodioxalane
- autoimmuneinflammation
- benzimidazole
- cancer
- amino
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201409194B true ZA201409194B (en) | 2017-08-30 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/09194A ZA201409194B (en) | 2012-06-27 | 2014-12-12 | Biflourodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (show.php) |
| EP (1) | EP2867237A1 (show.php) |
| JP (2) | JP6272846B2 (show.php) |
| KR (1) | KR102155559B1 (show.php) |
| CN (1) | CN104540831B (show.php) |
| AU (2) | AU2013283318B2 (show.php) |
| BR (1) | BR112014032581A8 (show.php) |
| CA (1) | CA2877589C (show.php) |
| EA (1) | EA029718B1 (show.php) |
| HK (1) | HK1204474A1 (show.php) |
| IL (1) | IL236463A0 (show.php) |
| IN (1) | IN2014MN02562A (show.php) |
| MX (1) | MX350418B (show.php) |
| MY (1) | MY167785A (show.php) |
| NZ (1) | NZ702618A (show.php) |
| SG (1) | SG11201408617PA (show.php) |
| UA (1) | UA116541C2 (show.php) |
| WO (1) | WO2014001464A1 (show.php) |
| ZA (1) | ZA201409194B (show.php) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2867237A1 (en) * | 2012-06-27 | 2015-05-06 | 4SC Discovery GmbH | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
| TWI807150B (zh) | 2014-03-20 | 2023-07-01 | 美商卡佩拉醫療公司 | 苯并咪唑衍生物及其醫藥組合物及使用方法 |
| KR102409739B1 (ko) | 2014-03-20 | 2022-06-17 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| WO2017053537A1 (en) | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| SI3440076T1 (sl) * | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| KR102733555B1 (ko) | 2017-10-27 | 2024-11-25 | 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 | 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법 |
| CN112912377A (zh) | 2018-09-13 | 2021-06-04 | 拜耳公司 | 作为害虫防治剂的杂环衍生物 |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| DK3643713T3 (da) * | 2018-10-23 | 2025-11-03 | Iomx Therapeutics Ag | Heterocykliske kinaseinhibitorer og deres anvendelse |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| CN101448506A (zh) | 2005-12-02 | 2009-06-03 | 拜尔健康护理有限责任公司 | 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物 |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| CN102574843B (zh) * | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
| EP2867237A1 (en) * | 2012-06-27 | 2015-05-06 | 4SC Discovery GmbH | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
-
2013
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en not_active Ceased
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 US US14/411,795 patent/US9580438B2/en not_active Expired - Fee Related
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko not_active Expired - Fee Related
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 HK HK15105006.4A patent/HK1204474A1/xx unknown
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014001464A1 (en) | 2014-01-03 |
| MX2014015938A (es) | 2015-07-21 |
| MY167785A (en) | 2018-09-25 |
| AU2013283318B2 (en) | 2017-11-23 |
| IN2014MN02562A (show.php) | 2015-07-24 |
| CN104540831A (zh) | 2015-04-22 |
| US20150158878A1 (en) | 2015-06-11 |
| KR20150037877A (ko) | 2015-04-08 |
| EP2867237A1 (en) | 2015-05-06 |
| HK1204474A1 (en) | 2015-11-20 |
| US9580438B2 (en) | 2017-02-28 |
| JP2018076360A (ja) | 2018-05-17 |
| SG11201408617PA (en) | 2015-01-29 |
| JP6272846B2 (ja) | 2018-01-31 |
| IL236463A0 (en) | 2015-02-26 |
| EA029718B1 (ru) | 2018-05-31 |
| NZ702618A (en) | 2016-12-23 |
| US20170240556A1 (en) | 2017-08-24 |
| BR112014032581A2 (pt) | 2017-06-27 |
| JP2015525742A (ja) | 2015-09-07 |
| EA201500050A1 (ru) | 2015-09-30 |
| UA116541C2 (uk) | 2018-04-10 |
| KR102155559B1 (ko) | 2020-09-15 |
| AU2018201275A1 (en) | 2018-03-15 |
| BR112014032581A8 (pt) | 2018-08-14 |
| CA2877589C (en) | 2019-11-26 |
| MX350418B (es) | 2017-09-06 |
| CN104540831B (zh) | 2017-11-07 |
| AU2013283318A1 (en) | 2015-01-22 |
| CA2877589A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201409194B (en) | Biflourodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| IL268340A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| SG10201912275YA (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders | |
| IL238400A0 (en) | Triazolopyrazines as brd4 inhibitors for use in cancer therapy | |
| IL244014A0 (en) | Combined therapy for the treatment of glioblastoma | |
| IL234639B (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| ZA201406706B (en) | Treatment of cancer with tor kinase inhibitors | |
| IL240672A0 (en) | Azabenzimidazole compounds that inhibit some 4pde enzymes and their use for the treatment of diseases related to the central nervous system | |
| IL234641A0 (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| ZA201501262B (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | |
| IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
| PL2817286T3 (pl) | Inhibitory kinazy do leczenia raka | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| IL237912B (en) | History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors |